Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion

[1] Stupp R(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-996

[2] Mason WP(2004)Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis Neuro Oncol 6 227-235

[3] van den Bent MJ(2009)Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 4733-4740

[4] Lamborn KR(2014)Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial Lancet Oncol 15 1100-1108

[5] Chang SM(2014)A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07) Neuro Oncol 16 92-102

[6] Prados MD(2012)Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02 Neuro Oncol 14 1511-1518

[7] Friedman HS(2013)Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma J Clin Oncol 31 3212-3218

[8] Prados MD(2014)Randomized phase II study of axitinib versus standard of care in patients with recurrent glioblastoma ASCO Meet Abstr 32 2018-953

[9] Wen PY(2014)Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial Lancet Oncol 15 943-2948

[10] Stupp R(2013)Vascular normalization as an emerging strategy to enhance cancer immunotherapy Cancer Res 73 2943-3659

[1] Stupp R(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-996

[2] Mason WP(2004)Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis Neuro Oncol 6 227-235

[3] van den Bent MJ(2009)Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 4733-4740

[4] Lamborn KR(2014)Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial Lancet Oncol 15 1100-1108

[5] Chang SM(2014)A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07) Neuro Oncol 16 92-102

[6] Prados MD(2012)Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02 Neuro Oncol 14 1511-1518

[7] Friedman HS(2013)Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma J Clin Oncol 31 3212-3218

[8] Prados MD(2014)Randomized phase II study of axitinib versus standard of care in patients with recurrent glioblastoma ASCO Meet Abstr 32 2018-953

[9] Wen PY(2014)Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial Lancet Oncol 15 943-2948

[10] Stupp R(2013)Vascular normalization as an emerging strategy to enhance cancer immunotherapy Cancer Res 73 2943-3659